deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04188379

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia

Sponsor: argenx

Conditions Primary Immune Thrombocytopenia
Interventions Placebo efgartigimod
Updated 24 times since 2020 Last updated: Feb 24, 2025 Started: Dec 16, 2019 Primary completion: Feb 3, 2022 Completion: Feb 3, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Primary Immune Thrombocytopenia, this trial is completed. The trial is conducted by argenx and has accumulated 24 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Apr 2022 · 6 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Apr 2024 · 13 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Apr 2024 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 19 earlier versions

  1. Mar 2023 — Apr 2024 [monthly]

    Completed PHASE3

  2. Apr 2022 — Mar 2023 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Oct 2021 — Apr 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  4. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  5. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  6. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  7. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE3

  8. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

  9. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  10. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE3

  11. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  12. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE3

  13. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  14. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  15. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE3

  16. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE3

  17. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE3

  18. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  19. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • argenx
Data source: argenx

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Adapazarı, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Barcelona, Spain , Bialystok, Poland , Brasschaat, Belgium , Brno, Czechia , Bruges, Belgium , Brzozów, Poland , Budapest, Hungary and 97 more locations